Enfuvirtide
Also known as: Fuzeon, T-20
Key Facts: Enfuvirtide
- Category
- Immune
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved but Commercially Discontinued (Feb 2025) - HIV salvage therapy. Withdrawn from US, UK, and Canadian markets due to availability of superior alternatives.
- Administration
- Subcutaneous injection twice daily
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- Ongoing as part of HIV regimen
Mechanism of Action
Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell.
Research Summary
TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
90 mg subcutaneous twice daily
Duration
Ongoing as part of HIV regimen
Administration
Subcutaneous injection twice daily
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Injection site reactions (98%)
- ●Diarrhea
- ●Nausea
- ●Fatigue
- ●Pneumonia (higher incidence)
- ●Hypersensitivity reactions
- ●FDA approved (Fuzeon)
References
- https://pubmed.ncbi.nlm.nih.gov/12637625/
- https://pubmed.ncbi.nlm.nih.gov/16477567/
- https://pubmed.ncbi.nlm.nih.gov/15907147/
Research This Peptide Further
Frequently Asked Questions
What does Enfuvirtide do?
A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
How does Enfuvirtide work?
Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell.
Is Enfuvirtide FDA approved?
Yes, Enfuvirtide is FDA approved. FDA Approved but Commercially Discontinued (Feb 2025) - HIV salvage therapy. Withdrawn from US, UK, and Canadian markets due to availability of superior alternatives.
What are the side effects of Enfuvirtide?
Reported side effects include: Injection site reactions (98%), Diarrhea, Nausea, Fatigue, Pneumonia (higher incidence). Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Enfuvirtide?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Subcutaneous injection twice daily. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Enfuvirtide or used in similar applications.
LL-37
Clinical TrialsA naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
ImmuneThymosin Alpha-1
Clinical TrialsA naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
ImmuneKPV
PreclinicalA tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
ImmuneVIP
Clinical TrialsA naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
ImmunePNC27
PreclinicalA chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
ImmuneThymogen
Clinical TrialsA synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
ImmuneWant updates on Enfuvirtide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.